Cargando…
Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications
[Image: see text] The coronavirus disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 116 million individuals globally and resulted in over 2.5 million deaths since the first report in December 2019. For most of this time,...
Autores principales: | Firestone, Tessa M., Oyewole, Opeoluwa O., Reid, St Patrick, Ng, Caroline L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009099/ https://www.ncbi.nlm.nih.gov/pubmed/33855275 http://dx.doi.org/10.1021/acsptsci.0c00222 |
Ejemplares similares
-
Discovery and repurposing of artemisinin
por: Shi, Qiaoli, et al.
Publicado: (2022) -
Split dosing of artemisinins does not improve antimalarial therapeutic efficacy
por: White, N. J., et al.
Publicado: (2017) -
Artemisinin Antimalarials: Preserving the “Magic Bullet”
por: Maude, Richard J, et al.
Publicado: (2010) -
DNA binding by the antimalarial compound artemisinin
por: Slavkovic, Sladjana, et al.
Publicado: (2022) -
Anticancer Effect of AntiMalarial Artemisinin Compounds
por: Das, AK
Publicado: (2015)